This website uses cookies to enhance the user experience.
||
S

SCANDIDERMA AS895 238 902

Process industry
Limited company
Stakkevollvegen 51 9010 TROMSØ, Norge
Industry and manufacturing
/ Process industry
/ 21.100 Manufacture of basic pharmaceutical products

SCANDIDERMA AS

Operating
Utvikle, produsere og selge kosmetiske ingredienser, samt engasjere seg i det som står i naturlig sammenheng med dette. Selskapet skal også kunne delta i andre selskaper med lignende økonomisk formål.
Produksjon av farmasøytiske råvarer og preparater.

Keywords

productionmedicinal substancesdrugsantibioticsbasic vitaminssalicylic acido-acetylsalicylic acidprocessing of blood

Organization

CEO
GH

Geir Håvard Kvalheim1977

Chairman of the board
GH

Geir Håvard Kvalheim1977

Years since formation
16 years
since Mar 2, 2010
Type
Limited company
VAT registered
No
Number of employees
0

Ownership

Number of shares and share classes
241,149
1 share class
Total number of shareholders
18
9 companies, 9 persons

Financials

Total operating income 2025
926,566
NOK
Annual total result 2025
834,824
NOK
Total equity 2025
-5,163,402
NOK
Last update: Jul 13, 2026

Management

Management / administration

NameRoleShares
GH

Geir Håvard Kvalheim

1977

Managing Director/CEO
17.6 %
indirectly

Board

NameRoleShares
GH

Geir Håvard Kvalheim

1977

Chairman
17.6 %
indirectly
EM

Edel Margrete Kandal

1958

Board Member
9.59 %
indirectly
KH

Kai-Hugo Hebnes

1978

Board Member
18.34 %
indirectly
CS

Carstein Seeberg

1962

Resigned		Board Member
14.15 %
indirectly

Top 10 individual shareholders

NameRoleShares
KH

Kai-Hugo Hebnes

1978

Board Member
18.34 %
indirectly
GH

Geir Håvard Kvalheim

1977

Managing Director/CEO, Chairman
17.6 %
indirectly
CS

Carstein Seeberg

1962

Board Member
14.15 %
indirectly
AK

Anton Kandal

1955

-
9.59 %
indirectly
EM

Edel Margrete Kandal

1958

Board Member
9.59 %
indirectly
IF

Ingmar Fimreite

1965

-
5.35 %
directly 4.15 %
indirectly 1.2 %
TE

Thomas Echroll

1977

-
3 %
indirectly
JE

Jo Erik Johnsrud Klaveness

1953

-
2.07 %
indirectly
RT

Rudi Thomassen

1980

-
2.07 %
indirectly
AR

Arild Rune Klakegg

1974

-
2.07 %
directly 1.87 %
indirectly 0.21 %
Last update: Sep 13, 2023

Ownership

Company shareholders

NameShare classTotal number of sharesShare
G
GHK INVEST AS
Ordinary shares
85,000
35.25 %
K
KANDAL INVEST AS
Ordinary shares
46,231
19.17 %
S
SEEBERG HOLDING AS
Ordinary shares
34,125
14.15 %
I
IMPETO AS
Ordinary shares
14,492
6.01 %
II

Inv International Montecristo

Ordinary shares
12,050
5 %
BJ

Bartosik Jacek

Ordinary shares
10,000
4.15 %
IF

Ingmar Fimreite

1965

Ordinary shares
10,000
4.15 %
D
DRUG DISCOVERY LABORATORY AS
Ordinary shares
5,000
2.07 %
R
R3 HOLDING AS
Ordinary shares
5,000
2.07 %
L
LAVOLD INVEST AS
Ordinary shares
5,000
2.07 %
AR

Arild Rune Klakegg

1974

Ordinary shares
4,500
1.87 %
F
FIMREITE AS
Ordinary shares
2,898
1.2 %
RL

Remi Lunde Solbakken

1987

Ordinary shares
2,173
0.9 %
AK

Andersen Knutsen Arthur

1983

Ordinary shares
1,449
0.6 %
BS

Bård Stian Nybø

1987

Ordinary shares
1,449
0.6 %
DE

Daniel Eriksen Martinsen

1978

Ordinary shares
641
0.27 %
CR

Christoffer Ryan

1987

Ordinary shares
641
0.27 %
K
KLAKEGG HOLDING AS
Ordinary shares
500
0.21 %
Last update: Jun 2, 2025

Financials

in NOK

Summary

Year20252024202320222021
Total operating income
926,566
1,255,666
1,053,429
2,702,100
850,857
Annual Total Result
834,824
1,207,592
-216,206
-948,397
-580,244
Total assets
33
416,343
409,850
3,378,654
2,743,778
Total liabilities
5,163,435
6,414,570
7,615,668
10,368,266
8,784,993
Total equity
-5,163,402
-5,998,226
-7,205,818
-6,989,612
-6,041,215

P&L

Year20252024202320222021
Total operating income
926,566
1,255,666
1,053,429
2,702,100
850,857
Total operating costs
91,734
162,239
1,269,592
3,646,446
972,735
Operating result
834,833
1,093,426
-216,163
-944,346
-121,878
Financial income/costs
-9
114,166
-43
-4,050
-458,365
Profit before tax
834,824
1,207,592
-216,206
-948,397
-580,244
Total tax & extraordinary income/cost
0
0
0
0
0
Annual Total Result
834,824
1,207,592
-216,206
-948,397
-580,244

Balance overview

Year20252024202320222021
Total fixed assets
0
383,125
383,125
530,033
831,829
Total current assets
33
33,218
26,725
2,848,620
1,911,949
Total assets
33
416,343
409,850
3,378,654
2,743,778
Short term debt
1,419,234
1,360,977
2,567,376
5,250,124
2,948,851
Long term debt
0
5,053,592
5,048,292
5,118,142
5,836,142
Total liabilities
5,163,435
6,414,570
7,615,668
10,368,266
8,784,993
Contributed capital
6,414,688
6,414,688
6,414,688
6,414,688
6,414,688
Retained earnings
-11,578,090
-12,412,914
-13,620,507
-13,404,300
-12,455,904
Total equity
-5,163,402
-5,998,226
-7,205,818
-6,989,612
-6,041,215
Total equity and liabilities
33
416,344
409,850
3,378,654
2,743,778

Classification

21st company classification
BETA
Small company
Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.1
Main industrial group
Manufacture of basic pharmaceutical products
21.10
Industrial group
Manufacture of basic pharmaceutical products
21.100
Industrial group
Manufacture of basic pharmaceutical products